(2026). Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). PLOS ONE.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Cancer Risk Associated with DPP4 Inhibitors in Type 2 Diabetes: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)."
PLOS ONE 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Cancer Risk Associated with DPP4 Inhibitors in Type 2 Diabetes: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)."
PLOS ONE, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.